Lung cancer interval times from point of referral to the acute health sector to the start of first treatment
Geraldine Largey A C , Eli Ristevski B , Helen Chambers B , Heather Davis A B and Peter Briggs A BA Southern Melbourne Integrated Cancer Service (SMICS), PO Box 72, 823-865 Centre Road, East Bentleigh, Vic. 3165, Australia.
B Monash University Department of Rural & Indigenous Health (MUDRIH), 3 Ollerton Avenue, Moe, Vic. 3825, Australia. Email: Eli.Ristevski@monash.edu; Helen.Chambers@monash.edu; Heather.Davis@monashhealth.org; Peter.Briggs@monashhealth.org
C Corresponding author. Email: geraldine.largey@monashhealth.org
Australian Health Review 40(6) 649-654 https://doi.org/10.1071/AH15220
Submitted: 14 September 2015 Accepted: 8 January 2016 Published: 25 February 2016
Abstract
Objective The aim of the present study was to compare lung cancer diagnostic and treatment intervals with agreed target measures across three large public health services in Victoria and assess any differences in interval times by treatment type and health service.
Methods A retrospective medical record audit of 78 patients admitted with a new diagnosis of lung cancer was conducted. Interval times from referral to diagnosis, diagnosis to first treatment and referral to first treatment were recorded in three treatment types: surgery, chemotherapy and radiotherapy.
Results There was a significant difference in the mean number of days from referral to diagnosis by treatment type. Patients who underwent surgery waited significantly longer (mean (± s.d.) 41.6 ± 38.4 days) to obtain a diagnosis than those who received radiotherapy (15.1 ± 18.6 days). Only 47% of surgical patients obtained a diagnosis within the recommended 28 days. Moreover, only 45% and 44% of patients, respectively, met the diagnosis-to-treatment target of 14 days and referral-to-treatment target of 42 days.
Conclusion The present study highlights the effect of treatment type on lung cancer referral interval times. It demonstrates the benefits of using evidenced-based interval target times to benchmark and compare performance outcomes in lung cancer.
What is known about the topic? Lung cancer is the leading cause of cancer mortality in Australia and has the lowest 5-year survival rate of all cancer types. Delays in the diagnosis of lung cancer can change the prognosis from potentially curable to incurable, particularly in faster-growing tumours.
What does this paper add? This study reveals treatment type was a greater factor in explaining variations in diagnosis and treatment than health service. Surgical patients were consistently lower in meeting the recommended interval targets across referral to diagnosis, diagnosis to treatment and referral to treatment.
What are the implications for practitioners? This study demonstrates the value of using evidenced-based interval target times to benchmark and compare performance outcomes in lung cancer. Such measures may further improve prognostic outcomes in lung cancer by reducing unwanted delays.
References
[1] Australian Institute of Health and Welfare (AIHW). Cancer in Australia: an overview 2014. Canberra: AIHW; 2014.[2] Wang T, Nelson RA, Bogardus A, Grannis FW. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010; 116 1518–25.
| Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival?Crossref | GoogleScholarGoogle Scholar | 20108308PubMed |
[3] Salomaa ER, Sallinen S, Hiekkanen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest 2005; 128 2282–8.
| Delays in the diagnosis and treatment of lung cancer.Crossref | GoogleScholarGoogle Scholar | 16236885PubMed |
[4] Ellis PM, Vandermeer R. Delays in the diagnosis of lung cancer. J Thorac Dis 2011; 3 183–8.
| 22263086PubMed |
[5] Cancer Australia. Best practice approaches to lung cancer care: a review of the literature. Surrey Hills, NSW: Cancer Australia; 2013.
[6] Stevens W. Recommendations to expedite the diagnosis of lung cancer. Final report of the HRC_DHBNZ funded project: “Identification of barriers to the early diagnosis of people with lung cancer and description of best practice solutions”. 2012. Available at: http://www.northerncancernetwork.org.nz/LinkClick.aspx?fileticket=Xgn%2BFhw6HAQ%3D&tabid=110&language=en-US [verified November 2015].
[7] Brown S, Castelli M, Hunter DJ, Erskine J, Vedsted P, Foot C, Rubin G. How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med 2014; 116 55–63.
[8] Walsh J, Harrison JD, Young JM, Butow PN, Solomon MJ, Masya L. What are the current barriers to effective cancer care coordination? A qualitative study. BMC Health Serv Res 2010; 10 132
| 20482884PubMed |
[9] Cancer Australia’s National Lung Cancer Program, Curtin University Project Team. Report on lung cancer in Australia: literature review and consultation on factors impacting on lung cancer outcomes. ACT: Australian Government; 2011.
[10] Mitchell PL, Thursfield VJ, Ball DL, Richardson GE, Irving LB, Torn-Broers Y, Giles GG, Wright GM. Lung cancer in Victoria: are we making progress? Med J Aust 2013; 199 674–9.
| Lung cancer in Victoria: are we making progress?Crossref | GoogleScholarGoogle Scholar | 24237097PubMed |
[11] Saint-Jacques N, Rayson D, Al-Fayea T, Virik K, Morzycki W, Younis T. Waiting times in early-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3 865–70.
| Waiting times in early-stage non-small cell lung cancer (NSCLC).Crossref | GoogleScholarGoogle Scholar | 18670304PubMed |
[12] National Institute for Health and Care Excellence (NICE). Treatment for non-small-cell lung cancer NICE pathway. Manchester: National Institute for Health and Care Excellence; 2015.
[13] Victorian Healthcare Association. Access to elective surgery in Victoria: position statement. Melbourne: Victorian Healthcare Association; 2014.
[14] Stirling RG, Evans SM, McLaughlin P, Senthuren M, Millar J, Gooi J, Irving L, Mitchell P, Haydon A, Ruben J, Conron M, Leong T, Watkins N, McNeill JJ. The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry. Lung 2014; 192 749–58.
| The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry.Crossref | GoogleScholarGoogle Scholar | 24907066PubMed |
[15] Jakobsen E, Green A, Oesterlind K, Rasmussen TR, Iachina M, Palshof T. Nationwide quality improvement in lung cancer care: the role of the Danish Lung Cancer Group and Registry. J Thorac Oncol 2013; 8 1238–47.
| Nationwide quality improvement in lung cancer care: the role of the Danish Lung Cancer Group and Registry.Crossref | GoogleScholarGoogle Scholar | 24457234PubMed |
[16] Largey G, Chakraborty S, Tobias T, Briggs P, Mazza D. Audit of referral pathways in the diagnosis of lung cancer: a pilot study. Aust J Primary Health 2015; 21 106–10.
| Audit of referral pathways in the diagnosis of lung cancer: a pilot study.Crossref | GoogleScholarGoogle Scholar |
[17] Wu L, Ashton CM. Chart review. A need for reappraisal. Eval Health Prof 1997; 20 146–63.
| Chart review. A need for reappraisal.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK1cvhsFeksg%3D%3D&md5=77cb11bc74bd7267badd5d1e9c2b2816CAS | 10183318PubMed |
[18] Metropolitan Health and Aged Care Services Division. Patient management framework. Lung tumour stream: non-small cell lung cancer, a guide to cancer care. Melbourne: Victorian Government Department of Human Services; 2006.
[19] Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd Revised Edition. Little BC, editor. Boston; Lippincott Williams and Wilkins; 1991.
[20] Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C, Anderson RS, Hamilton W, Oleson F, Rose P, Nafees S, Muth C, Beyer M, Neal RD. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer 2012; 106 1262–7.
| The Aarhus statement: improving design and reporting of studies on early cancer diagnosis.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38vms1Gjtw%3D%3D&md5=5d7d7a3aca6783ba751bb9246064c38fCAS | 22415239PubMed |
[21] Walter F, Webster A, Scott S, Emery J. The Andersen model of total patient delay: a systematic review of its application in cancer diagnosis. J Health Serv Res Policy 2012; 17 110–18.
| The Andersen model of total patient delay: a systematic review of its application in cancer diagnosis.Crossref | GoogleScholarGoogle Scholar | 22008712PubMed |
[22] Singh H, Hirani K, Kadiyala H, Rudomiotov O, Davis T, Khan MM, Wahls TL. Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study. J Clin Oncol 2010; 28 3307–15.
| Characteristics and predictors of missed opportunities in lung cancer diagnosis: an electronic health record-based study.Crossref | GoogleScholarGoogle Scholar | 20530272PubMed |
[23] Sawicki M, Szczyrek M, Krawczyk P, Rybojad P, Jablonka A, Milanowski J. Reasons for delay in diagnosis and treatment of lung cancer among patients in Lublin Voivodeship who were consulted in Thoracic Surgery Department. Ann Agric Environ Med 2013; 20 72–6.
| 23540215PubMed |
[24] Faris N, Yu X, Sareen S, Signore RS, McHugh LM, Roark K, Robbins ET, Osarogiagon RU. Preoperative evaluation of lung cancer in a community health care setting. Ann Thorac Surg 2015; 100 394–400.
| Preoperative evaluation of lung cancer in a community health care setting.Crossref | GoogleScholarGoogle Scholar | 26074001PubMed |
[25] Akash V, Chopra A, Lim A, Tai D, Goh S, Kor A, Ho B, Basheer D, Lee YW, Abisheganaden J. Timeliness of in-hospital journey of suspected lung cancer patients: from first presentation-to-start of therapy. Int J Cancer Res Molec Mechan 2015;
| Timeliness of in-hospital journey of suspected lung cancer patients: from first presentation-to-start of therapy.Crossref | GoogleScholarGoogle Scholar |
[26] Aisner DL, Marshall CB. Molecular pathology of non-small cell lung cancer: a practical guide. Am J Clin Pathol 2012; 138 332–46.
| Molecular pathology of non-small cell lung cancer: a practical guide.Crossref | GoogleScholarGoogle Scholar | 22912349PubMed |
[27] Australian Institute of Health and Welfare (AIHW). Elective surgery waiting list episode: clinical urgency, code N. Metadata online registry. 2015. Available at: http://meteor.aihw.gov.au/content/index.phtml/itemId/270008 [verified 4 February 2016].
